Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics

Journal of Mass Spectrometry

Volumn 48, Issue 11, 2013, Pages 1150-1159

  Moosmann, Bjoern ^a,b   Huppertz, Laura M ^a   Hutter, Melanie ^a,b   Buchwald, Armin ^a   Ferlaino, Sascha ^b   Auwärter, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

benzodiazepines; flubromazepam; immunoassay; LC MS MS; serum; urine

Indexed keywords

BENZODIAZEPINES; FLUBROMAZEPAM; IMMUNOASSAY; LC-MS/MS; SERUM; URINE;

ASSAYS; BODY FLUIDS; COMMERCE; DRUG DOSAGE; DRUG PRODUCTS; GAS CHROMATOGRAPHY; INDUCTIVELY COUPLED PLASMA; LIQUID CHROMATOGRAPHY; METABOLISM; ORGANIC POLYMERS; PHARMACOKINETICS; PHYSIOLOGY;

DESIGN;

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; DRUG METABOLITE; FLUBROMAZEPAM; FLUNITRAZEPAM; N DESMETHYL FLUNITRAZEPAM; NORDAZEPAM; PHENAZEPAM; UNCLASSIFIED DRUG; DESIGNER DRUG; MICROCAPSULE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DEBROMINATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; DRUG MISUSE; DRUG SCREENING; DRUG URINE LEVEL; DRUG USE; FATIGUE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOCHEMISTRY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; SIDE EFFECT; SLEEP TIME; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; BLOOD; CHEMISTRY; MICROCAPSULE; URINE;

ADULT; BENZODIAZEPINES; CAPSULES; DESIGNER DRUGS; HUMANS;

EID: 84888154809     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3279     Document Type: Article

References (21)

1. EMCDDA reporting form on the new drug pyrazolam. REITOX, Finland, 2012, accessible via the EDND database of the EMCDDA.
2. B. Moosmann, M. Hutter, L. Huppertz, S. Ferlaino, L. Redlingshöfer, V. Auwärter,. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol. 2013, 31, 263.
3. J. B. Hester, P. Von Voigtlander,. 6-Aryl-4H-s-triazolo[4,3-a][1,4] benzodiazepines. Influence of 1-substitution on pharmacological activity. J. Med. Chem. 1979, 22, 1390.
4. L. H. Sternbach, R. I. Fryer, W. Metlesics, E. Reeder, G. Sach, G. Saucy, A. Stempel,. Quinazolines and 1,4-benzodiazepines. VI.1a halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones1b,c. J. Org. Chem. 1962, 27, 3788.
5. L. H. Sternbach, R. I. Fryer, W. Metlesics, G. Sach, A. Stempel,. Quinazolines and 1,4-benzodiazepines. V. o-aminobenzophenones. J. Org. Chem. 1962, 27, 3781.
6. L. H. Sternbach, L. O. Randall, R. Banziger, H. Lehr,. In Drugs Affecting the Central Nervous System, A. Burger, (Eds). Edward Arnold, London, 1968.
7. P. Griffiths, R. Sedefov, A. Gallegos, D. Lopez,. How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study, Addiction 2010, 105, 951.
8. Alprazolam, European Pharmacopoeia, 7th ed., Council of Europe, 2007, available at: http://www.edqm.eu/en/european-pharmacopoeia-7th-edition-1401.html
9. H. H. Maurer, K. Pfleger, A. A. Weber,. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, 4th ed., Wiley-VCH, Weinheim, 2011.
10. A. L. Ekonomov, A. P. Rodionov, V. P. Zherdev, Y. I. Vikhlyaev,. 7-Bromo-5-(2'-chlorophenyl)-1, 3-dihydro-2H-1, 4-benzodiazepin-2-one (I), a new tranquillizing agent: metabolism in rats. Xenobiotica 1979, 9, 503.
11. V. P. Zherdev, S. Caccia, S. Garattini, A. L. Ekonomov,. Species differences in phenazepam kinetics and metabolism. Eur. J. Drug Metab. Pharmacokinet. 1982, 7, 191.
12. P. D. Maskell, G. De Paoli, L. Nitin Seetohul, D. J. Pounder,. Phenazepam: the drug that came in from the cold. J. Forensic Leg. Med. 2012, 19, 122.
13. Recommended methods for the detection and assay of barbiturates and benzodiazepines in biological specimens. Manual for use by National laboratories, United Nations Office on Drugs and Crime 1997 UN document ID number: ST/NAR/28.
14. M. J. Cho, T. A. Scahill, J. B. Hester,. Kinetics and equilibrium of the reversible alprazolam ring-opening reaction. J. Pharm. Sci. 1983, 72, 356.
15. M. Gerecke,. Chemical structure and properties of midazolam compared with other benzodiazepines. Br. J. Clin. Pharmacol. 1983, 16, 11S.
16. E. S. Baird, D. M. Hailey,. Plasma levels of diazepam and its major metabolite following intramuscular administration. Br. J. Anaesth. 1973, 45, 546.
17. R. Sellman, J. Kanto, J. Pekkarinen,. Biliary Excretion of diazepam and its metabolites in man. Acta Pharmacol. Toxicol. 1975, 37, 242.
18. J. R. M. Caplehorn, O. H. Drummer,. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust. N. Z. J. Public Health 2002, 26, 358.
19. M. Reynaud, G. Petit, D. Potard, P. Courty,. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93, 1385.
20. S. Darke, D. Zador,. Fatal heroin 'overdose': a review. Addiction 1996, 91, 1765.
21. E. Tanaka,. Toxicological interactions between alcohol and benzodiazepines. Clin. Toxicol. 2002, 40, 69.